echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Performance overview of 20 large API enterprises in 2017

    Performance overview of 20 large API enterprises in 2017

    • Last Update: 2017-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [market analysis of chinapharma.com] 2017 is about to pass This year, the pharmaceutical industry has both joys and sorrows Take the API industry for example, the market demand is increasing day by day, but the pressure brought by environmental protection also makes the API enterprises breathless Now, the fourth quarter of 2017 will be over In order to help you better understand the performance of API enterprises this year, the following summarizes the performance of relevant enterprises Northeast Pharmaceutical (VC leading enterprise, is gradually out of the business dilemma): in the first three quarters of 2017, it achieved a revenue of 4.191 billion yuan, an increase of 12.22% year-on-year; the net profit attributable to the parent company was 79.8609 million yuan, an increase of 1213.92% year-on-year VC prices continued to rise, contributing to performance flexibility, and private placement was approved smoothly Harbin Pharmaceutical Group: in the first three quarters of 2017, the operating revenue was 9.21 billion yuan, a year-on-year decrease of 10.96%; the net profit attributable to shareholders of listed companies was 260 million yuan, a year-on-year decrease of 56.84% Lukang Pharmaceutical (antibiotic leading enterprise): in the first three quarters of 2017, the operating revenue was 1884134313.66 yuan, an increase of 3.87% year on year, and the net profit attributable to shareholders of listed companies was 43569305.73 yuan, an increase of 101.73% year on year Huabei Pharmaceutical (leading enterprise of antibiotics and VC): in the first three quarters of 2017, its operating revenue was 5.698 billion yuan, down 4.66% year on year; its net profit was 21.7121 million yuan, down 66.4707% year on year Originally, its vitamin C production capacity was second only to that of Northeast Pharmaceutical, but it missed this round of growth dividend due to many factors such as production suspension and relocation required by environmental inspection Shiyao group (raw materials such as vitamins, antibiotics, antipyretics and analgesics): in the first three quarters of 2017, its revenue was about HK $11.208 billion (about RMB 9.52 billion), up 21.2% year on year Net profit was HK $2.043 billion, up 30.4% year on year Brother Technology: in the first three quarters of 2017, the net profit attributable to the parent company was 250 million yuan, with a year-on-year increase of 157.91%; the company's core profit varieties VB1, VK3 and niacinamide are all in the price rising cycle New pantothenate production capacity has been put into operation in the four quarter, and production capacity has been released to maintain low position Considering the large capacity of pantothenic calcium market, supply and demand can still maintain a tight balance, the price is expected to remain high in the future, the company can continue to share the market, the company's 700 million yuan convertible bonds are publicly raised, and the share price is converted to 18.17 yuan The first phase of the project is expected to proceed smoothly, and it is expected to be put into operation in the fourth quarter of 2018 New Hecheng: the company's operating revenue in the first three quarters of 2017 was 4.092 billion yuan, an increase of 19.57% year-on-year, and the non net profit deducted increased by 6.39% year-on-year, that is, 861 million non net profit was deducted in the first three quarters of 2017 Corresponding to the non net profit of 304 million yuan in the third quarter of 2017, a slight decrease of 0.41% year-on-year The basic earnings per share in the first three quarters was 0.83 yuan, up 6.41% year on year The price rise of vitamin A and vitamin H, the main products of the company's nutrition sector, started in the middle and last ten days of August The proportion of long-term product orders was low in the third quarter The sales revenue of vitamin varieties decreased year-on-year, and the profit fell slightly, which was in line with the expectation The three quarter increased operating income mainly from methionine production and flavor and spice prices Zhejiang Pharmaceutical: its revenue in the first three quarters of 2017 was 3.918 billion yuan, down 1.38% year on year; the net profit attributable to shareholders of listed companies was 131 million yuan, down 67.55% year on year BASF and other black swan events continue to improve the prosperity of VA and VE The company's new 5000 ton production line of VA (500000 IU) is expected to be put into production in March 2018, and the quotation of VA in the domestic market has reached 840 yuan / kg When the annual output of VA (500000 IU) is 3000 tons, the annual net profit of VA can reach more than 1.4 billion yuan, with considerable performance flexibility Jindawei: in the first three quarters of 2017, it achieved revenue of 1.37 billion (+ 14%), net profit attributable to the parent of 240 million (+ 23%), net profit attributable to the parent after deducting non profits of 230 million (+ 18%); in the single quarter of 2017q3, it achieved revenue of 470 million (+ 19%), net profit attributable to the parent of 91.18 million (+ 38%), net profit attributable to the parent after deducting non profits of 82.62 million (+ 28%); it was predicted that in 2017, net profit attributable to the parent of 400-540 million, a year-on-year increase of 35-80% Yifan pharmaceutical: in the first three quarters of 2017, its operating revenue and net profit attributable to its parent were 3.07 billion yuan and 880 million yuan respectively, with a year-on-year growth rate of 14.8% and 63.4% respectively; its net profit after deducting non profits was 830 million yuan, with a year-on-year growth rate of 55.6% The price increase of calcium pantothenate significantly improved performance The growth rate of the company's revenue and performance in the first three quarters was higher than the market expectation Huayuan biology: in the first three quarters of 2017, the company achieved an operating revenue of 310 million yuan, a year-on-year increase of 39.06%; the net profit attributable to the shareholders of the listed company was 103 million yuan, a year-on-year increase of 287.42%, and the non parent net profit was 97.7649 million yuan, a year-on-year increase of 359, 62% The increase of vitamin D3 volume and price drives the company's performance to grow rapidly The company focuses on the upstream and downstream distribution of vitamin D3, and its main products include vitamin D3, 25 hydroxyvitamin D3, NF cholesterol, etc The quarter on quarter growth of operating revenue of 9.0% and the quarter on quarter growth of net profit of 28.8% fully demonstrate the reversal trend of andissu's performance With the price increase of core products, continuous process improvement and strict cost control, the whole series of andissu products have achieved strong growth and maintained a good profit level Guangji pharmaceutical: in the first three quarters of 2017, revenue reached 554 million yuan, up 47.5% year on year; net profit reached 125 million yuan (loss in the same period last year) Q3 achieved a revenue of 237 million yuan, a net profit of 67.93 million yuan (slight profit in the same period last year), and a quarter on quarter growth rate of 101% (quarter on quarter growth rate of 47%) Since the beginning of this year, the price of vitamin B2, the leading product, has increased, driving the growth of performance According to the financial report of modern pharmaceutical (Sinopharm Group Pharmaceutical platform, leading enterprise in antibiotic industry): the net profit attributable to the owner of the parent company in the first three quarters of 2017 was 446 million yuan, an increase of 16.14% over the same period of last year; the operating revenue was 6.587 billion yuan, a decrease of 0.59% over the same period of last year Xinhua Pharmaceutical (the leading enterprise of antipyretic and analgesic APIs, with half of the pharmaceutical business): in the first three quarters of 2017, it is estimated that the net profit will be RMB 152 million to RMB 196 million; the net profit of Guimu will increase by 70-120% year-on-year; the prices of antipyretic and analgesic APIs such as caffeine, ibuprofen, analgin and aspirin will continue to rise, and the API sector of the company is expected to significantly increase profits Xianju Pharmaceutical Co., Ltd (a leading steroid drug enterprise): in the first three quarters of 2017, the company achieved a revenue of 1.989 billion yuan, a year-on-year increase of 9.16%, a net profit attributable to the parent of 141 million yuan, an increase of 40.09%, and eps0.15 yuan, which is in line with the expectation The gross profit margin of sales in the first three quarters reached 55%, rising for four consecutive quarters, and the proportion of preparation varieties kept increasing In the first three quarters, the gross profit margin of the company's sales reached 55%, rising for three consecutive quarters, with the previous value of 54% and 50% respectively There are two reasons for the increase of gross profit rate: on the one hand, the proportion of high gross profit rate preparations has increased; on the other hand, the price of vitamin D3, the API, has increased Kelun pharmaceutical: in the first three quarters of 2017, the net profit attributable to the parent company was 386 million yuan, a year-on-year decrease of 28.10%; 6-APA and 7-ACA are in the price rising cycle, and it is expected to accelerate the release of production capacity in the fourth quarter after the environmental protection acceptance of CHUANNING phase II UL (the former leader of antibiotics and the current insulin star): in the first half of 2017, it achieved revenue of 3.34 billion yuan (the same unit below), a year-on-year increase of 12.7%; net profit of 109 million yuan, a year-on-year loss of 13.48 million yuan The realization of turning loss into profit mainly benefited from the improvement of capacity utilization rate of main intermediates and API products represented by 6-APA, the improvement of production cost, and the increase of sales volume of related products year on year The company's antibiotic business bottomed out and rebounded in 2017, ushering in a performance turning point The rapid development and comprehensive layout of insulin business will become a major focus in the future Huahai Pharmaceutical Co., Ltd (leading enterprise of sartan API, model of preparation export): in the first three quarters of 2017, the company achieved an operating revenue of 3.510 billion yuan, a year-on-year increase of 20.11%; the net profit attributable to shareholders of listed companies was 485 million yuan, a year-on-year increase of 25.94% The net profit attributable to shareholders of listed companies deducting non recurring profit and loss was 409 million yuan, an increase of 16.26% year on year Qianhong Pharmaceutical (heparin leader): the operating revenue in the first three quarters was 757152771.75 yuan, an increase of 40.53% year on year, and the net profit attributable to shareholders of listed companies was 171376761.25 yuan, a decrease of 6.9% year on year Original title: performance overview of 20 large API enterprises in 2017
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.